Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial91
CAR T-cell therapy comes of age: Introductory editorial for the special issue61
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation56
Clinical applications of circulating tumor DNA in Hodgkin lymphoma51
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia49
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies48
How to set up a clinical research center in Brazil, as an example of a middle-income country41
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-1929
Updates on current and future research in acute myeloid leukemia25
Epidemiology and etiology of diffuse large B-cell lymphoma24
Lessons learned from the Eµ-TCL1 mouse model of CLL22
Somatic mutations in “benign” blood diseases21
The role of viruses in HIV-associated lymphomas20
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services20
TET2 mutation as prototypic clonal hematopoiesis lesion19
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence19
Antibody and immunotherapy in diffuse large B-cell lymphoma17
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future17
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors16
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?16
Vaccinations in patients with chronic lymphocytic leukemia14
The molecular map of CLL and Richter's syndrome14
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics13
Tribute to an editor: Neal S. Young As a Medical Editor and Writer13
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients13
T-cell engaging antibodies for B-cell lymphomas13
Clonal hematopoiesis13
outside front cover, PMS 8883 metallic AND 4/C12
outside front cover, PMS 8883 metallic AND 4/C12
Cellular and immunotherapies for myelodysplastic syndromes12
outside front cover, PMS 8883 metallic AND 4/C11
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations11
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia10
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead9
The biology of classical Hodgkin lymphoma9
Aplastic anemia: Quo vadis?9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy9
Challenges and opportunities of CAR T-cell therapies for CLL9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana9
Somatic compensation of inherited bone marrow failure8
The pediatric approach to Hodgkin lymphoma8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)8
Understanding MDS stem cells: Advances and limitations8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS8
Somatic mutations in acquired pure red cell aplasia8
Menin inhibition for the treatment of acute leukemia8
Harnessing single-domain antibodies for CAR-T and bispecific antibody development8
Clinical applications of circulating tumor DNA in central nervous system lymphoma7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials7
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia7
DLBCL arising from indolent lymphomas: How are they different?7
The crossroads of cancer therapies and clonal hematopoiesis7
0.17921280860901